What's in Uniquity One (UNI)'s pipeline?

Uniquity One (UNI) has 6 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 6 in Phase 2, 0 in Phase 1.

Which companies overlap with Uniquity One (UNI)'s portfolio?

Top competitors by shared drug class: Novo Nordisk A/S, SCRI Development Innovations, LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/uniquity-one-uni.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Uniquity One (UNI) — Portfolio Competitive Intelligence Brief

Uniquity One (UNI) pipeline: 0 marketed, 0 filed, 0 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 6 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Inflammation · 1
Inflammatory diseases · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Novo Nordisk A/S · 1 shared drug class
SCRI Development Innovations, LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Uniquity One (UNI):

Cite this brief

Drug Landscape (2026). Uniquity One (UNI) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/uniquity-one-uni. Accessed 2026-05-16.